ResMed has launched a rebrand to unify its portfolio and reflect its increasing direct-to-consumer engagement.
Analysts, including those from Needham and Oppenheimer, flagged risks that Medicare coverage and increasing adoption of GLP-1 therapies could reduce demand for ResMed’s core CPAP devices over time.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results